Zynerba Pharmaceuticals is engaged in pharmaceutically-produced transdermal cannabinoid therapies for neuropsychiatric disorders. Co. is focused on improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Co. is developing Zygel, the pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting treatment of behavioral symptoms of FXS, ASD and 22q. We show 35 historical shares outstanding datapoints in our ZYNE shares outstanding history coverage, used to compute ZYNE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ZYNE market cap history over the course of time is important for investors
interested in comparing ZYNE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ZYNE versus a peer is one thing; comparing
ZYNE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ZYNE can fluctuate over the course of history.
With this page we aim to empower investors researching ZYNE by allowing them to research the ZYNE market cap history. |
Free ZYNE Email Alerts:
Video: The Importance of Market Cap
